Royalty Pharma (RPRX)
32.24
0.29 (0.91%)
At close: Apr 14, 2025, 3:46 PM
0.91% (1D)
| Bid | 32.23 |
| Market Cap | 13.97B |
| Revenue (ttm) | 2.26B |
| Net Income (ttm) | 858.77M |
| EPS (ttm) | 1.91 |
| PE Ratio (ttm) | 16.88 |
| Forward PE | 7.63 |
| Analyst | Buy |
| Ask | 32.25 |
| Volume | 1,858,836 |
| Avg. Volume (20D) | 5,560,967.6 |
| Open | 32.22 |
| Previous Close | 31.95 |
| Day's Range | 31.77 - 32.28 |
| 52-Week Range | 24.05 - 34.20 |
| Beta | 0.49 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pha...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2020
Employees 75
Stock Exchange NASDAQ
Ticker Symbol RPRX
Website https://www.royaltypharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for RPRX stock is "Buy." The 12-month stock price forecast is $45.5, which is an increase of 41.13% from the latest price.
Stock ForecastsNext Earnings Release
Royalty Pharma is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+12.56%
Royalty Pharma shares are trading higher after the...
Unlock content with
Pro Subscription
